Agenus shared on LinkedIn:
“Today updated Phase 2 NEST results reporting longer follow-up with neoadjuvant BOT+BAL in resectable colon cancer was published in Clinical Cancer Research.
The findings add to the clinical and biological rationale for evaluating BOT+BAL earlier in disease, where treatment is delivered with curative intent and the immune system may still be positioned to generate a coordinated anti-tumor response.
Agenus’ planned global Phase 3 ROBBIN trial evaluating neoadjuvant BOT+BAL in curative-intent MSS/pMMR colon cancer is expected to open in Q1 2027.
Read The Full Release.
Title: Neoadjuvant Botensilimab/Balstilimab for localized mismatch repair proficient and deficient colon cancer: Results of the NEST phase 2 clinical trial
Authors: Manish A. Shah, Erika Hissong, Mehraneh D. Jafari, Pashtoon Murtaza. Kasi, Maider Astorkia, Sahrish Khan, Casey Owens, Zhengming Chen, Heather Yeo, Fabio Socciarelli, Sandipto Sarkar, Alana Nguyen, Despina Siolas, Allyson Ocean, Kelly Garrett, Lea Lowenfeld, Alessio Pigazzi, Preethi Guniganti, Sanjay Patel, Doron Betel, Manuel Hidalgo.
Read The Full Manuscript.”
You can also read: Agenus Announces Up to $340M Financing to Advance Phase 3 ROBBIN Trial in MSS Colon Cancer
